DENVER — Boulder-based Biodesix Inc. and Array BioPharma Inc. (Nasdaq: ARRY) were recognized Thursday by the Colorado Bioscience Association for their contributions to the state’s life science industry in 2019.
Biodesix, a commercial-stage pharmaceutical that focuses on cancer treatments, won the association’s Company of the Year award. Boulder’s Brickell Biotech Inc. (Nasdaq: BBI) was a finalist in this category.
Array, a company developing rapid-screen tests for lung cancer, received the association’s Deal of the Year award. The firm announced in June it would be acquired by pharmaceutical giant Pfizer Inc. (NYSE: PFE) in a deal estimated to be worth about $11 billion.
“Health innovations from Colorado make a global impact. Our celebration highlighted our life sciences ecosystem’s commitment to sharing opportunities and breakthroughs by our members that save and change lives,” Colorado Bioscience Association president Jennifer Jones Paton said in a prepared statement. “Congratulations to our honorees, finalists and award winners. They inspire all of us with their passion and dedication.”